Recently, a meta-analysis invalidated the use of VPA for reasons other than seizure control in patients with newly diagnosed GBM outside clinical trials [50], suggesting the limitations of single medication with GSK3β-inhibitory drug. The gene discussed is GSK3B; the disease is glioblastoma.